COMMUNIQUÉS West-GlobeNewswire
-
Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases
13/07/2026 -
Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth
13/07/2026 -
GutGlucose Releases Latest Ingredients List with Gut Glucose Reset Formula
13/07/2026 -
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
13/07/2026 -
BreathEaseX Releases Sublingual Lung Health Spray with CardioEaseX Formula for Easy Breathing Support
13/07/2026 -
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
13/07/2026 -
Sienna Senior Living Named One of Canada's Best Companies by TIME and Statista for Second Consecutive Year
13/07/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
13/07/2026 -
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
13/07/2026 -
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
13/07/2026 -
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026 -
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026 -
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
13/07/2026 -
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
13/07/2026 -
Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference
13/07/2026 -
BrewDog Waterloo to Host England's Biggest Pub Watch Party for Blockbuster Semifinal
13/07/2026 -
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
13/07/2026 -
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
13/07/2026 -
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026
Pages